CA3025933A1 - Use of ezh2 inhibitors for treating cancer - Google Patents

Info

Publication number

CA3025933A1

CA3025933A1 CA3025933A CA3025933A CA3025933A1 CA 3025933 A1 CA3025933 A1 CA 3025933A1 CA 3025933 A CA3025933 A CA 3025933A CA 3025933 A CA3025933 A CA 3025933A CA 3025933 A1 CA3025933 A1 CA 3025933A1

Authority

CA

Canada

Prior art keywords

cancer

alkyl

immune checkpoint

inhibitor

checkpoint inhibitor

Prior art date

2016-06-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 199
• 239000003112 inhibitor Substances 0.000 title claims abstract description 191
• 201000011510 cancer Diseases 0.000 title claims abstract description 141
• 101150090105 Ezh2 gene Proteins 0.000 title 1
• 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 246
• 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract description 223
• 238000000034 method Methods 0.000 claims abstract description 185
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 158
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 158
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims abstract description 157
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims abstract description 157
• NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims abstract description 69
• 229950004774 tazemetostat Drugs 0.000 claims abstract description 68
• 210000004027 cell Anatomy 0.000 claims description 169
• -1 cyano, hydroxyl Chemical group 0.000 claims description 148
• 150000001875 compounds Chemical class 0.000 claims description 147
• 239000000203 mixture Substances 0.000 claims description 106
• 125000005843 halogen group Chemical group 0.000 claims description 93
• 150000003839 salts Chemical class 0.000 claims description 87
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 82
• 238000011282 treatment Methods 0.000 claims description 75
• 208000026310 Breast neoplasm Diseases 0.000 claims description 64
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 64
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 60
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 58
• 206010006187 Breast cancer Diseases 0.000 claims description 56
• 125000003118 aryl group Chemical group 0.000 claims description 55
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 53
• 125000003545 alkoxy group Chemical group 0.000 claims description 51
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 45
• 125000001424 substituent group Chemical group 0.000 claims description 44
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
• 125000005842 heteroatom Chemical group 0.000 claims description 38
• 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 28
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 25
• 201000001441 melanoma Diseases 0.000 claims description 24
• 125000004429 atom Chemical group 0.000 claims description 22
• 229960003852 atezolizumab Drugs 0.000 claims description 20
• 229960002621 pembrolizumab Drugs 0.000 claims description 20
• 229960003301 nivolumab Drugs 0.000 claims description 18
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
• 238000009472 formulation Methods 0.000 claims description 17
• 230000001394 metastastic effect Effects 0.000 claims description 17
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 17
• 206010009944 Colon cancer Diseases 0.000 claims description 16
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 15
• 208000029742 colonic neoplasm Diseases 0.000 claims description 15
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
• 125000003386 piperidinyl group Chemical group 0.000 claims description 13
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 12
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 12
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 12
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
• 208000020816 lung neoplasm Diseases 0.000 claims description 12
• 201000005962 mycosis fungoides Diseases 0.000 claims description 12
• 201000000849 skin cancer Diseases 0.000 claims description 12
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
• 201000005202 lung cancer Diseases 0.000 claims description 11
• 229910052717 sulfur Inorganic materials 0.000 claims description 11
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
• 206010025323 Lymphomas Diseases 0.000 claims description 10
• 206010039491 Sarcoma Diseases 0.000 claims description 10
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
• 210000000056 organ Anatomy 0.000 claims description 10
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
• 238000009097 single-agent therapy Methods 0.000 claims description 10
• 206010004593 Bile duct cancer Diseases 0.000 claims description 9
• 206010018338 Glioma Diseases 0.000 claims description 9
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
• 206010038389 Renal cancer Diseases 0.000 claims description 9
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
• 150000001450 anions Chemical class 0.000 claims description 9
• 230000002496 gastric effect Effects 0.000 claims description 9
• 201000010982 kidney cancer Diseases 0.000 claims description 9
• 201000002528 pancreatic cancer Diseases 0.000 claims description 9
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 claims description 9
• 208000008732 thymoma Diseases 0.000 claims description 9
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
• 208000002458 carcinoid tumor Diseases 0.000 claims description 8
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
• 229950009791 durvalumab Drugs 0.000 claims description 8
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 7
• 102100038078 CD276 antigen Human genes 0.000 claims description 7
• 101710185679 CD276 antigen Proteins 0.000 claims description 7
• 208000032612 Glial tumor Diseases 0.000 claims description 7
• 101150046249 Havcr2 gene Proteins 0.000 claims description 7
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
• 241000282414 Homo sapiens Species 0.000 claims description 7
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
• 208000034578 Multiple myelomas Diseases 0.000 claims description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 7
• 229950002916 avelumab Drugs 0.000 claims description 7
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 7
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
• 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 6
• 208000021309 Germ cell tumor Diseases 0.000 claims description 6
• 206010061252 Intraocular melanoma Diseases 0.000 claims description 6
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
• 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 6
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 6
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 6
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 6
• 201000000582 Retinoblastoma Diseases 0.000 claims description 6
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
• 201000005969 Uveal melanoma Diseases 0.000 claims description 6
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 6
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 6
• 125000002632 imidazolidinyl group Chemical group 0.000 claims description 6
• 210000002865 immune cell Anatomy 0.000 claims description 6
• 229960005386 ipilimumab Drugs 0.000 claims description 6
• 210000004153 islets of langerhan Anatomy 0.000 claims description 6
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 6
• 125000002757 morpholinyl group Chemical group 0.000 claims description 6
• 201000008106 ocular cancer Diseases 0.000 claims description 6
• 201000002575 ocular melanoma Diseases 0.000 claims description 6
• 125000000160 oxazolidinyl group Chemical group 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 125000004193 piperazinyl group Chemical group 0.000 claims description 6
• 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 6
• 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 6
• 210000002784 stomach Anatomy 0.000 claims description 6
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
• 206010046766 uterine cancer Diseases 0.000 claims description 6
• 208000037965 uterine sarcoma Diseases 0.000 claims description 6
• 206010003571 Astrocytoma Diseases 0.000 claims description 5
• 208000017604 Hodgkin disease Diseases 0.000 claims description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
• 125000002393 azetidinyl group Chemical group 0.000 claims description 5
• 239000002775 capsule Substances 0.000 claims description 5
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
• 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 5
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
• 229940126586 small molecule drug Drugs 0.000 claims description 5
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 5
• 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 claims description 5
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
• 229940125565 BMS-986016 Drugs 0.000 claims description 4
• 206010005003 Bladder cancer Diseases 0.000 claims description 4
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
• 229940125568 MGD013 Drugs 0.000 claims description 4
• 206010027406 Mesothelioma Diseases 0.000 claims description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
• 210000000988 bone and bone Anatomy 0.000 claims description 4
• 229950004270 enoblituzumab Drugs 0.000 claims description 4
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
• 229940121569 ieramilimab Drugs 0.000 claims description 4
• 210000004185 liver Anatomy 0.000 claims description 4
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
• 210000000130 stem cell Anatomy 0.000 claims description 4
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
• 208000030507 AIDS Diseases 0.000 claims description 3
• 206010061424 Anal cancer Diseases 0.000 claims description 3
• 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
• 206010073360 Appendix cancer Diseases 0.000 claims description 3
• 206010060971 Astrocytoma malignant Diseases 0.000 claims description 3
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
• 206010006143 Brain stem glioma Diseases 0.000 claims description 3
• 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 3
• 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
• 206010007275 Carcinoid tumour Diseases 0.000 claims description 3
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 3
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 206010014733 Endometrial cancer Diseases 0.000 claims description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
• 206010014967 Ependymoma Diseases 0.000 claims description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
• 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims description 3
• 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
• 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 3
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 3
• 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 3
• 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 3
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 3
• 206010025537 Malignant anorectal neoplasms Diseases 0.000 claims description 3
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 3
• 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
• 208000000172 Medulloblastoma Diseases 0.000 claims description 3
• 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 3
• 206010027407 Mesothelioma malignant Diseases 0.000 claims description 3
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
• 206010029260 Neuroblastoma Diseases 0.000 claims description 3
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
• 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 3
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 3
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
• 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 3
• 206010033268 Ovarian low malignant potential tumour Diseases 0.000 claims description 3
• 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
• 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
• 206010034299 Penile cancer Diseases 0.000 claims description 3
• 206010050487 Pinealoblastoma Diseases 0.000 claims description 3
• 208000007641 Pinealoma Diseases 0.000 claims description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
• 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
• 208000009359 Sezary Syndrome Diseases 0.000 claims description 3
• 208000021388 Sezary disease Diseases 0.000 claims description 3
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
• 206010057644 Testis cancer Diseases 0.000 claims description 3
• 206010043515 Throat cancer Diseases 0.000 claims description 3
• 201000009365 Thymic carcinoma Diseases 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
• 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 claims description 3
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 3
• 206010046431 Urethral cancer Diseases 0.000 claims description 3
• 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 206010047741 Vulval cancer Diseases 0.000 claims description 3
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
• 208000008383 Wilms tumor Diseases 0.000 claims description 3
• 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
• 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
• 210000002255 anal canal Anatomy 0.000 claims description 3
• 201000011165 anus cancer Diseases 0.000 claims description 3
• 208000021780 appendiceal neoplasm Diseases 0.000 claims description 3
• 208000012172 borderline epithelial tumor of ovary Diseases 0.000 claims description 3
• 201000002143 bronchus adenoma Diseases 0.000 claims description 3
• 201000007455 central nervous system cancer Diseases 0.000 claims description 3
• 201000007335 cerebellar astrocytoma Diseases 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 201000004677 childhood cerebellar astrocytic neoplasm Diseases 0.000 claims description 3
• 201000008522 childhood cerebral astrocytoma Diseases 0.000 claims description 3
• 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 3
• 230000002357 endometrial effect Effects 0.000 claims description 3
• 201000004101 esophageal cancer Diseases 0.000 claims description 3
• 208000024519 eye neoplasm Diseases 0.000 claims description 3
• 201000010175 gallbladder cancer Diseases 0.000 claims description 3
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
• 201000010536 head and neck cancer Diseases 0.000 claims description 3
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
• 201000006866 hypopharynx cancer Diseases 0.000 claims description 3
• 230000002267 hypothalamic effect Effects 0.000 claims description 3
• 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims description 3
• 210000000244 kidney pelvis Anatomy 0.000 claims description 3
• 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 208000019420 lymphoid neoplasm Diseases 0.000 claims description 3
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
• 210000000716 merkel cell Anatomy 0.000 claims description 3
• 208000037970 metastatic squamous neck cancer Diseases 0.000 claims description 3
• 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 3
• 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 claims description 3
• 210000000653 nervous system Anatomy 0.000 claims description 3
• 201000011682 nervous system cancer Diseases 0.000 claims description 3
• 201000005443 oral cavity cancer Diseases 0.000 claims description 3
• 201000006958 oropharynx cancer Diseases 0.000 claims description 3
• 201000008968 osteosarcoma Diseases 0.000 claims description 3
• 208000021284 ovarian germ cell tumor Diseases 0.000 claims description 3
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 3
• 201000003113 pineoblastoma Diseases 0.000 claims description 3
• 208000010916 pituitary tumor Diseases 0.000 claims description 3
• 208000010626 plasma cell neoplasm Diseases 0.000 claims description 3
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
• 206010038038 rectal cancer Diseases 0.000 claims description 3
• 201000001275 rectum cancer Diseases 0.000 claims description 3
• 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 claims description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
• 201000008261 skin carcinoma Diseases 0.000 claims description 3
• 201000002314 small intestine cancer Diseases 0.000 claims description 3
• 206010042863 synovial sarcoma Diseases 0.000 claims description 3
• 201000003120 testicular cancer Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 210000000626 ureter Anatomy 0.000 claims description 3
• 230000002485 urinary effect Effects 0.000 claims description 3
• 201000009825 uterine corpus cancer Diseases 0.000 claims description 3
• 206010046885 vaginal cancer Diseases 0.000 claims description 3
• 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
• 210000000239 visual pathway Anatomy 0.000 claims description 3
• 230000004400 visual pathway Effects 0.000 claims description 3
• 201000005102 vulva cancer Diseases 0.000 claims description 3
• 229940125563 LAG3 inhibitor Drugs 0.000 claims description 2
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
• 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
• 201000000053 blastoma Diseases 0.000 claims description 2
• 201000008184 embryoma Diseases 0.000 claims description 2
• 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 claims description 2
• 208000028591 pheochromocytoma Diseases 0.000 claims description 2
• 230000002123 temporal effect Effects 0.000 claims description 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 8
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
• 239000012271 PD-L1 inhibitor Substances 0.000 claims 2
• 229940121656 pd-l1 inhibitor Drugs 0.000 claims 2
• 230000002490 cerebral effect Effects 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 147
• 230000002062 proliferating effect Effects 0.000 description 118
• 208000035475 disorder Diseases 0.000 description 78
• 201000010099 disease Diseases 0.000 description 69
• 238000011277 treatment modality Methods 0.000 description 63
• 125000000217 alkyl group Chemical group 0.000 description 60
• 230000002829 reductive effect Effects 0.000 description 56
• 125000003282 alkyl amino group Chemical group 0.000 description 44
• 230000000694 effects Effects 0.000 description 41
• 125000003342 alkenyl group Chemical group 0.000 description 28
• 230000003902 lesion Effects 0.000 description 27
• 150000001413 amino acids Chemical class 0.000 description 24
• 210000000481 breast Anatomy 0.000 description 24
• 238000002648 combination therapy Methods 0.000 description 24
• 239000012453 solvate Substances 0.000 description 24
• 125000000304 alkynyl group Chemical group 0.000 description 23
• 238000006243 chemical reaction Methods 0.000 description 23
• 230000005764 inhibitory process Effects 0.000 description 23
• 102000056255 human EZH2 Human genes 0.000 description 22
• 239000008194 pharmaceutical composition Substances 0.000 description 22
• 230000004083 survival effect Effects 0.000 description 21
• 210000001519 tissue Anatomy 0.000 description 20
• 125000001072 heteroaryl group Chemical group 0.000 description 19
• 125000004432 carbon atom Chemical group C* 0.000 description 18
• 239000003814 drug Substances 0.000 description 18
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
• 229910052757 nitrogen Inorganic materials 0.000 description 18
• 229910052701 rubidium Inorganic materials 0.000 description 18
• 230000000875 corresponding effect Effects 0.000 description 17
• 125000000623 heterocyclic group Chemical group 0.000 description 17
• 238000001990 intravenous administration Methods 0.000 description 17
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 16
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 16
• 210000001072 colon Anatomy 0.000 description 16
• 210000004072 lung Anatomy 0.000 description 16
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 15
• 230000030833 cell death Effects 0.000 description 15
• 230000035772 mutation Effects 0.000 description 15
• 238000001802 infusion Methods 0.000 description 14
• 208000006994 Precancerous Conditions Diseases 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• 108010033040 Histones Proteins 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 12
• 210000003491 skin Anatomy 0.000 description 12
• 229940124597 therapeutic agent Drugs 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 11
• 229910052799 carbon Inorganic materials 0.000 description 11
• 150000002148 esters Chemical class 0.000 description 11
• 206010020718 hyperplasia Diseases 0.000 description 11
• 238000005259 measurement Methods 0.000 description 11
• 239000000546 pharmaceutical excipient Substances 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
• 102000006947 Histones Human genes 0.000 description 10
• 229910003827 NRaRb Inorganic materials 0.000 description 10
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000002401 inhibitory effect Effects 0.000 description 10
• 210000001672 ovary Anatomy 0.000 description 10
• 210000000496 pancreas Anatomy 0.000 description 10
• 210000002307 prostate Anatomy 0.000 description 10
• 108090000623 proteins and genes Proteins 0.000 description 10
• 102000011787 Histone Methyltransferases Human genes 0.000 description 9
• 108010036115 Histone Methyltransferases Proteins 0.000 description 9
• 206010054949 Metaplasia Diseases 0.000 description 9
• 125000004442 acylamino group Chemical group 0.000 description 9
• 235000001014 amino acid Nutrition 0.000 description 9
• 229940024606 amino acid Drugs 0.000 description 9
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 229910052736 halogen Inorganic materials 0.000 description 9
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
• 230000015689 metaplastic ossification Effects 0.000 description 9
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 206010058314 Dysplasia Diseases 0.000 description 8
• 229910019142 PO4 Inorganic materials 0.000 description 8
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 8
• 150000007942 carboxylates Chemical class 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 125000004663 dialkyl amino group Chemical group 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 150000002367 halogens Chemical class 0.000 description 8
• 235000021317 phosphate Nutrition 0.000 description 8
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical group C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 102000055027 Protein Methyltransferases Human genes 0.000 description 7
• 108700040121 Protein Methyltransferases Proteins 0.000 description 7
• 229940124639 Selective inhibitor Drugs 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
• 125000003277 amino group Chemical group 0.000 description 7
• 125000001769 aryl amino group Chemical group 0.000 description 7
• 125000005129 aryl carbonyl group Chemical group 0.000 description 7
• 230000028993 immune response Effects 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
• 239000010452 phosphate Substances 0.000 description 7
• 235000018102 proteins Nutrition 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 7
• 125000004434 sulfur atom Chemical group 0.000 description 7
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 238000003419 tautomerization reaction Methods 0.000 description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 6
• 125000004947 alkyl aryl amino group Chemical group 0.000 description 6
• 125000002877 alkyl aryl group Chemical group 0.000 description 6
• 125000004414 alkyl thio group Chemical group 0.000 description 6
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 6
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 6
• 201000005389 breast carcinoma in situ Diseases 0.000 description 6
• 125000004986 diarylamino group Chemical group 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 150000003384 small molecules Chemical class 0.000 description 6
• 230000004614 tumor growth Effects 0.000 description 6
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
• 102000017578 LAG3 Human genes 0.000 description 5
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 5
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 5
• 210000005096 hematological system Anatomy 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 5
• 125000005647 linker group Chemical group 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 239000008177 pharmaceutical agent Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
• 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 229940125431 BRAF inhibitor Drugs 0.000 description 4
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
• 206010061818 Disease progression Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 4
• 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 4
• 125000005110 aryl thio group Chemical group 0.000 description 4
• 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 150000001768 cations Chemical class 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 230000005750 disease progression Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 102000015694 estrogen receptors Human genes 0.000 description 4
• 108010038795 estrogen receptors Proteins 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 230000002962 histologic effect Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 201000011059 lobular neoplasia Diseases 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 102000003998 progesterone receptors Human genes 0.000 description 4
• 108090000468 progesterone receptors Proteins 0.000 description 4
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 4
• 210000005005 sentinel lymph node Anatomy 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 125000003003 spiro group Chemical group 0.000 description 4
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 102000052609 BRCA2 Human genes 0.000 description 3
• 108700020462 BRCA2 Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 101150008921 Brca2 gene Proteins 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• 101150029707 ERBB2 gene Proteins 0.000 description 3
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 3
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
• 108010044467 Isoenzymes Proteins 0.000 description 3
• 208000010191 Osteitis Deformans Diseases 0.000 description 3
• 208000027868 Paget disease Diseases 0.000 description 3
• 230000018199 S phase Effects 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 3
• 230000032823 cell division Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 3
• 208000027202 mammary Paget disease Diseases 0.000 description 3
• 238000007069 methylation reaction Methods 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 125000004076 pyridyl group Chemical group 0.000 description 3
• 125000000714 pyrimidinyl group Chemical group 0.000 description 3
• 229910052702 rhenium Inorganic materials 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 231100001274 therapeutic index Toxicity 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 125000005960 1,4-diazepanyl group Chemical group 0.000 description 2
• 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 2
• FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 108010074708 B7-H1 Antigen Proteins 0.000 description 2
• 102000008096 B7-H1 Antigen Human genes 0.000 description 2
• 108700020463 BRCA1 Proteins 0.000 description 2
• 102000036365 BRCA1 Human genes 0.000 description 2
• 101150072950 BRCA1 gene Proteins 0.000 description 2
• 206010006189 Breast cancer in situ Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 208000000321 Gardner Syndrome Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
• 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 201000005027 Lynch syndrome Diseases 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010070308 Refractory cancer Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000003158 alcohol group Chemical group 0.000 description 2
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003435 aroyl group Chemical group 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 208000019493 atypical carcinoid tumor Diseases 0.000 description 2
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 150000001555 benzenes Chemical class 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 201000003714 breast lobular carcinoma Diseases 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 208000030239 cerebral astrocytoma Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 231100000517 death Toxicity 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 230000001973 epigenetic effect Effects 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000029824 high grade glioma Diseases 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 208000024312 invasive carcinoma Diseases 0.000 description 2
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 201000008632 juvenile polyposis syndrome Diseases 0.000 description 2
• 125000000468 ketone group Chemical group 0.000 description 2
• 208000003849 large cell carcinoma Diseases 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000030883 malignant astrocytoma Diseases 0.000 description 2
• 201000011614 malignant glioma Diseases 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 208000021039 metastatic melanoma Diseases 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical class N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 208000000649 small cell carcinoma Diseases 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 125000005415 substituted alkoxy group Chemical group 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 208000023747 urothelial carcinoma Diseases 0.000 description 2
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• 125000005955 1H-indazolyl group Chemical group 0.000 description 1
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
• 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 1
• XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• PDBXHPORMXSXKO-UHFFFAOYSA-N 8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione;hydron;chloride Chemical compound Cl.N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 PDBXHPORMXSXKO-UHFFFAOYSA-N 0.000 description 1
• 208000037068 Abnormal Karyotype Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 208000004804 Adenomatous Polyps Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010072813 Breast angiosarcoma Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000035865 Chronic mast cell leukemia Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010071161 Colon dysplasia Diseases 0.000 description 1
• 208000019399 Colonic disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 238000012287 DNA Binding Assay Methods 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 208000033640 Hereditary breast cancer Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 229940123309 Immune checkpoint modulator Drugs 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 239000012270 PD-1 inhibitor Substances 0.000 description 1
• 239000012668 PD-1-inhibitor Substances 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000035199 Tetraploidy Diseases 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000026487 Triploidy Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 231100000071 abnormal chromosome number Toxicity 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
• 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000003322 aneuploid effect Effects 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000005512 benztetrazolyl group Chemical group 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 201000009613 breast lymphoma Diseases 0.000 description 1
• 208000029610 breast phyllodes tumor Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000004623 carbolinyl group Chemical group 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 201000002797 childhood leukemia Diseases 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000004049 epigenetic modification Effects 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 210000001280 germinal center Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
• 150000002390 heteroarenes Chemical class 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 150000004680 hydrogen peroxides Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 238000010820 immunofluorescence microscopy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 125000004926 indolenyl group Chemical group 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000005438 isoindazolyl group Chemical group 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 208000029565 malignant colon neoplasm Diseases 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 239000003697 methyltransferase inhibitor Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 238000011294 monotherapeutic Methods 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 208000004707 mucinous cystadenoma Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000010309 neoplastic transformation Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940100692 oral suspension Drugs 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 208000002820 pancreatoblastoma Diseases 0.000 description 1
• 208000030314 papillary cystic neoplasm Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 229940121655 pd-1 inhibitor Drugs 0.000 description 1
• 201000009612 pediatric lymphoma Diseases 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000004932 phenoxathinyl group Chemical group 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 150000004885 piperazines Chemical group 0.000 description 1
• 125000004928 piperidonyl group Chemical group 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000003476 primary myelofibrosis Diseases 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 230000019639 protein methylation Effects 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 150000003354 serine derivatives Chemical class 0.000 description 1
• 208000005893 serous cystadenoma Diseases 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 201000010700 sporadic breast cancer Diseases 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
• 229930192474 thiophene Chemical group 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000037426 transcriptional repression Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 150000003852 triazoles Chemical group 0.000 description 1
• 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1